Twist Bioscience Corp banner

Twist Bioscience Corp
F:0ME

Watchlist Manager
Twist Bioscience Corp Logo
Twist Bioscience Corp
F:0ME
Watchlist
Price: 39.78 EUR 1.82%
Market Cap: €2.3B

Wall Street
Price Targets

0ME Price Targets Summary
Twist Bioscience Corp

Wall Street analysts forecast 0ME stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0ME is 37.65 EUR with a low forecast of 28.31 EUR and a high forecast of 47.42 EUR.

Lowest
Price Target
28.31 EUR
29% Downside
Average
Price Target
37.65 EUR
5% Downside
Highest
Price Target
47.42 EUR
19% Upside
Twist Bioscience Corp Competitors:
Price Targets
ZEAL
Zealand Pharma A/S
72% Upside
HCAT
Health Catalyst Inc
84% Upside
PWP
Perella Weinberg Partners
-5% Downside

Revenue
Forecast

56% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
56% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

For the last 8 years the compound annual growth rate for Twist Bioscience Corp's revenue is 56%. The projected CAGR for the next 3 years is 16%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 0ME's stock price target?
Price Target
37.65 EUR

According to Wall Street analysts, the average 1-year price target for 0ME is 37.65 EUR with a low forecast of 28.31 EUR and a high forecast of 47.42 EUR.

What is Twist Bioscience Corp's Revenue forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Twist Bioscience Corp's revenue is 56%. The projected CAGR for the next 3 years is 16%.

Back to Top